Results 51 to 60 of about 217,987 (265)
CIS of the bladder: a review of literature
Carcinoma in situ (CIS) of the bladder poses a clinical challenge to urologists worldwide. The clinical course of CIS ranges from benign, indolent tumor growth to highly progressive tumor proliferation with deleterious effects on patient outcome and ...
Ahmed Fouad Kotb +2 more
doaj +1 more source
The graphical abstract illustrates that sublethal thermal stress after iRFA upregulates the chaperone CRYAB in residual HCC cells, which stabilizes β‐catenin and drives a dual pathological program, including EMT and N2‐TAN polarization, thereby leading to heterotypic CTC cluster formation. The MMP‐9‐responsive hydrogel (XB@Gel) delivers XAV‐939 and BMS‐
Hui Chen +8 more
wiley +1 more source
Background and purpose: Breast ductal carcinoma in situ with microinvasion (DCIS-MI) is considered to be the interim stage in the progression from breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).
李 爽, 郎冠天, 余科达
doaj
p53-protein over-expression and gene mutational of oral carcinoma in-situ
We had been reported histological types of oral carcinoma in-situ (oral CIS), such as basaloid, verrucous, and acanthothic/ atrophic types. We considered that they have different histological appearance influenced by molecular behavior. To understand the
Mei Syafriadi, Takashi Saku
doaj +1 more source
Carcinoma in situ of the bladder
Abstract Five cases of carcinoma in situ of the urinary bladder are reviewed. The clinical features, difficulties in diagnosis, and surgical management are discussed.
openaire +2 more sources
Mutant KRAS‐m6A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target
Mutant KRAS‐m6A axis promotes colorectal cancer (CRC) progression. Mutant KRAS stabilizes METTL3, leading to increased m6A‐modified BCL9L mRNA and translation of BCL9L protein. BCL9L in turn mediates TGF‐β secretion to induce differentiation of Treg and an immunosuppressive microenvironment.
Danyu Chen +12 more
wiley +1 more source
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu +13 more
wiley +1 more source
Potential biomarkers of ductal carcinoma in situ progression
Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni +17 more
doaj +1 more source
In breast cancer (BC) pathogenesis models, normal cells acquire somatic mutations and there is a stepwise progression from high-risk lesions and ductal carcinoma in situ to invasive cancer. The precancer biology of mammary tissue warrants better characterization to understand how different BC subtypes emerge.
Bychkovsky, Brittany L. +4 more
openaire +3 more sources
Design and Application of Nanozymes: Current Trends and Cutting‐Edge Breakthroughs
Advanced Science, EarlyView.
Kelong Fan, Hui Wei, Xiyun Yan
wiley +1 more source

